China NMPA Drug Inspection - Guizhou Hanfang Pharmaceutical Co., Ltd. - Qinghuo Yangyuan Capsules

On March 17, 2021, the Guizhou Provincial Drug Administration, acting under the National Medical Products Administration (NMPA), issued its first drug quality announcement for the year (Issue 43) to ensure public medication safety. The report highlights a quality failure involving Guizhou Hanfang Pharmaceutical Co., Ltd. Following a planned sampling and inspection series, one specific batch of Qinghuo Yangyuan Capsules (Batch Number 2538006, 0.5g per capsule) was found to be non-compliant with established quality requirements. The inspection, conducted by the Guizhou Provincial Institute for Food and Drug Control, determined that the product failed to meet the National Drug Standard WS-10700(ZD0700)-2002-2012Z. Specifically, the violation concerned the physical appearance of the medication. This regulatory action was carried out under the framework of the Drug Administration Law of the People's Republic of China and the Administrative Measures for Drug Quality Sampling and Inspection. In response to these findings, the Guizhou Provincial Drug Administration has initiated formal legal cases for further investigation and punishment of the company. The administration is also increasing its oversight to ensure the manufacturer corrects all illegal practices and strengthens its risk prevention and control measures. These steps are part of a broader effort to maintain rigorous drug quality standards and protect the health of consumers within the province.